Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease

Trends in Neurosciences

Volumn 30, Issue 5, 2007, Pages 244-250

  Sulzer, David ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; NEUROMELANIN;

CELL DEATH; CELL LOSS; DOPAMINERGIC NERVE CELL; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALS; DOPAMINE; HUMANS; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 34247631275     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2007.03.009     Document Type: Review

References (70)

1. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 11 (1959) 490-493
2. Zarow C., et al. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60 (2003) 337-341
3. Clark L.N., et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology (2006)
4. Wirdefeldt K., et al. No evidence for heritability of Parkinson disease in Swedish twins. Neurology 63 (2004) 305-311
5. Piccini P., et al. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann. Neurol. 45 (1999) 577-582
6. Tanner C.M., et al. Parkinson disease in twins: an etiologic study. JAMA. 281 (1999) 341-346
7. Sveinbjornsdottir S., et al. Familial aggregation of Parkinson's disease in Iceland. N. Engl. J. Med. 343 (2000) 1765-1770
8. Braak H., et al. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 21 (2006) 2042-2051
9. German D.C., and Manaye K.F. Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat. J. Comp. Neurol. 331 (1993) 297-309
10. Oorschot D.E. Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods. J. Comp. Neurol. 366 (1996) 580-599
11. Roberts R.C., et al. Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse 45 (2002) 78-85
12. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann. N. Y. Acad. Sci. 991 (2003) 1-14
13. Barnes T.D., et al. Activity of striatal neurons reflects dynamic encoding and recoding of procedural memories. Nature 437 (2005) 1158-1161
14. Schultz W. Getting formal with dopamine and reward. Neuron 36 (2002) 241-263
15. Grace A.A., and Bunney B.S. The control of firing pattern in nigral dopamine neurons: single spike firing. J. Neurosci. 4 (1984) 2866-2876
16. Puopolo M., et al. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J. Neurosci. 27 (2007) 645-656
17. Omelchenko N., and Sesack S.R. Laterodorsal tegmental projections to identified cell populations in the rat ventral tegmental area. J. Comp. Neurol. 483 (2005) 217-235
18. Kuznetsov A.S., et al. Transient high-frequency firing in a coupled-oscillator model of the mesencephalic dopaminergic neuron. J. Neurophysiol. 95 (2006) 932-947
19. Damier P., et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (1999) 1437-1448
20. Liang C.L., et al. Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration 5 (1996) 313-318
21. Wilson C.J., and Callaway J.C. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J. Neurophysiol. 83 (2000) 3084-3100
22. Liss B., and Roeper J. ATP-sensitive potassium channels in dopaminergic neurons: transducers of mitochondrial dysfunction. News Physiol. Sci. 16 (2001) 214-217
23. Seutin V., et al. Sulfonylurea-sensitive potassium current evoked by sodium-loading in rat midbrain dopamine neurons. Neuroscience 71 (1996) 709-719
24. Liss B., et al. The weaver mouse gain-of-function phenotype of dopaminergic midbrain neurons is determined by coactivation of wvGirk2 and K-ATP channels. J. Neurosci. 19 (1999) 8839-8848
25. Liss B., et al. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat. Neurosci. 8 (2005) 1742-1751
26. Sulzer D., and Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox. Res. 1 (2000) 181-195
27. Nakamura K., et al. Tetrahydrobiopterin scavenges superoxide in dopaminergic neurons. J. Biol. Chem. 276 (2001) 34402-34407
28. Staal R.G., et al. Dopamine neurons release transmitter via a flickering fusion pore. Nat. Neurosci. 7 (2004) 341-346
29. Sulzer D., and Pothos E.N. Presynaptic mechanisms that regulate quantal size. Rev. Neurosci. 11 (2000) 159-212
30. Mosharov E.V., et al. Intracellular patch electrochemistry: regulation of cytosolic catecholamines in chromaffin cells. J. Neurosci. 23 (2003) 5835-5845
31. Fahn S., and Sulzer d. Neurodegeneration and neuroprotection in Parkinson's Disease. NeuroRx 1 (2004) 139-154
32. Compagni A., and Christofori G. Recent advances in research on multistage tumorigenesis. Br. J. Cancer 83 (2000) 1-5
33. Sulzer D., et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 11869-11874
34. Larsen K.E., and Sulzer D. Autophagy in neurons: a review. Histol. Histopathol. 17 (2002) 897-908
35. Zecca L., et al. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci. 26 (2003) 578-580
36. Ulfig N. Altered lipofuscin pigmentation in the basal nucleus (Meynert) in Parkinson's disease. Neurosci. Res. 6 (1989) 456-462
37. Liang C.L., et al. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. J. Comp. Neurol. 473 (2004) 97-106
38. McNaught K.S., et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 56 (2004) 149-162
39. Beal F., and Lang A. The proteasomal inhibition model of Parkinson's disease: "boon or bust"?. Ann. Neurol. 60 (2006) 158-161
40. Arrasate M., et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431 (2004) 805-810
41. Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
42. Von Coelln R., et al. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10744-10749
43. Tan J.M., and Dawson T.M. Parkin blushed by PINK1. Neuron 50 (2006) 527-529
44. Shimura H., et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293 (2001) 263-269
45. Paxinou E., et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21 (2001) 8053-8061
46. Rideout H.J., et al. Proteasomal inhibition leads to formation of ubiquitin/α-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78 (2001) 899-908
47. LaVoie M.J., et al. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11 (2005) 1214-1221
48. Massey A.C., et al. Consequences of the selective blockage of chaperone-mediated autophagy. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5805-5810
49. Norris E.H., et al. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280 (2005) 21212-21219
50. Volles M.J., et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001) 7812-7819
51. Mosharov E., et al. Alpha-synuclein overexpression permeabilizes secretory vesicles and increases cytosolic catecholamine. J. Neurosci. 26 (2006) 9304-93311
52. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
53. Hasbani D.M., et al. Dopamine depletion does not protect against acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in vivo. J. Neurosci. 25 (2005) 9428-9433
54. Ved R., et al. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of α-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J. Biol. Chem. 280 (2005) 42655-42668
55. Linda H., et al. Expression of MHC class I heavy chain and β2-microglobulin in rat brainstem motoneurons and nigral dopaminergic neurons. J. Neuroimmunol. 101 (1999) 76-86
56. German D.C., et al. Mid-brain dopaminergic cell loss in Parkinson's Disease: computer visualization. Ann. Neurol. 26 (1989) 507-514
57. Hirsch E., et al. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334 (1988) 345-348
58. Eckert T., et al. Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging. Mov Disord (2006)
59. Sieradzan K.A., and Mann D.M. The selective vulnerability of nerve cells in Huntington's disease. Neuropathol. Appl. Neurobiol. 27 (2001) 1-21
60. Hawkes C. Olfaction in neurodegenerative disorder. Mov. Disord. 18 (2003) 364-372
61. Polymeropoulos M.H., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
62. Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
63. Singleton A.B., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
64. Kirik D., et al. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22 (2002) 2780-2791
65. Vila M., et al. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74 (2000) 721-729
66. Kholodilov N.G., et al. Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J. Neurochem. 73 (1999) 2586-2599
67. Larsen K.E., et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 26 (2006) 11915-11922
68. Fortin D.L., et al. Neural activity controls the synaptic accumulation of α-synuclein. J. Neurosci. 25 (2005) 10913-10921
69. Raghavan R., et al. Alpha-synuclein expression in the developing human brain. Pediatr. Dev. Pathol. 7 (2004) 506-516
70. Kingsbury A.E., et al. Alteration in α-synuclein mRNA expression in Parkinson's disease. Mov. Disord. 19 (2004) 162-170